Using Olaparib for Advanced Prostate Cancer
Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer: An Observational Study
Santa Chiara Hospital · NCT06783127
This study is testing how well the drug olaparib works for men with advanced prostate cancer who have specific genetic changes, to see if it helps them live longer and feel better.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 3000 (estimated) |
| Sex | Male |
| Sponsor | Santa Chiara Hospital (other) |
| Locations | 2 sites (Naples and 1 other locations) |
| Trial ID | NCT06783127 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the overall survival and clinical outcomes of patients with metastatic castration-resistant prostate cancer (mCRPC) who are treated with olaparib in a real-world clinical setting. It will analyze both retrospective and prospective data from multiple centers to identify predictive and prognostic factors associated with treatment outcomes. The study focuses specifically on patients with BRCA mutations, providing insights into the effectiveness of olaparib for this subgroup.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with BRCA mutant metastatic castration-resistant prostate cancer who are receiving olaparib treatment in clinical practice.
Not a fit: Patients who are currently enrolled in a clinical trial involving olaparib will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable information on the effectiveness of olaparib for improving survival in patients with advanced prostate cancer.
How similar studies have performed: While there have been studies on olaparib for other cancers, this specific approach in mCRPC with a focus on BRCA mutations is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: BRCA mutant Metastatic castration-resistant prostate cancer patients treatment with olaparib in clinical practice Exclusion Criteria: Olaparib treatment in a clinical trial
Where this trial is running
Naples and 1 other locations
- Sabrina Rossetti — Naples, Italy (RECRUITING)
- Orazio Caffo — Trento, Italy (RECRUITING)
Study contacts
- Study coordinator: Orazio Caffo, MD
- Email: orazio.caffo@apss.tn.it
- Phone: +390461902478
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Prostate Cancer, Castrate Resistant Prostate Cancer, BRCA Mutation